| Literature DB >> 31274411 |
Cam Escoffery1, Kara Riehman2, Lesley Watson3, A Sandy Priess3, Marcie Fisher Borne3, Sean Nathaniel Halpin4, Carlie Rhiness4, Emily Wiggins4, Michelle C Kegler4.
Abstract
PURPOSE ANDEntities:
Mesh:
Substances:
Year: 2019 PMID: 31274411 PMCID: PMC6638585 DOI: 10.5888/pcd16.180406
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Characteristics of FQHCs (N = 9) Participating in Qualitative Interviews in a Study of Facilitators and Barriers to Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program, May–August 2016
| FQHC | Outcome | Contextual Factors | Implementation Strategies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FQHC ID No. | State (No. of Clinics in System) | Baseline HPV Vaccination Initiation Rate, % | Percentage-Point Change in HPV Vaccination Initiation | Funding Level | Urbanicity | Target Patient Population in 2015 | Strong EHR Capabilities | 75% of Staff Trained | Client Reminders | Provider Prompts | Standing Orders | Provider Assessment and Feedback |
| 1 | North Carolina (10) | 72.6 | 23.4 | Technical assistance | Urban | 904 | ||||||
| 2 | Maryland (5) | 46.4 | 22.2 | Technical assistance | Rural | 926 |
|
|
| |||
| 3 | California (5) | 73.0 | No data | $10,000 | Rural | 661 | √ | |||||
| 4 | Maine (13) | 52.3 | 4.2 | $10,000 | Rural | 1,666 |
|
|
|
|
|
|
| 5 | Florida (6) | 64.8 | 24.9 | $90,000 | Urban | 1,613 |
|
|
|
|
| |
| 6 | South Carolina (22) | 74.8 | −18.7 | $90,000 | Mixed | 2,777 |
| |||||
| 7 | Alabama (10) | 71.2 | 12.3 | $90,000 | Mixed | 1,541 |
|
|
| |||
| 8 | California (10) | 15.8 | 45.4 | $90,000 | Suburban | 1,862 |
| |||||
| 9 | West Virginia (13) | 11.4 | 3.9 | $90,000 | Rural | 745 |
| |||||
Abbreviation: √, FQHC has characteristic; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
Themes of Less Frequently Mentioneda Facilitators or Barriers, Aligned by Domains of the Consolidated Framework for Implementation Research, in Qualitative Interviews in a Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program in Federally Qualified Health Centers, May–August 2016
| Domain/Theme | No. of FQHCs Noting Barrier | Description of Facilitator or Barrier |
|---|---|---|
|
| ||
|
| ||
| Teamwork | 3 | Although it was important to have a champion to help encourage ongoing support of the project, it was also critical to have team members who were willing to work together to achieve a common goal across the hierarchy. These teams typically consisted of both clinical staff (eg, nurses, medical assistants, physicians) and nonclinicians (eg, quality managers). |
|
| ||
| Compatibility with other similar projects | 3 | The VACs project was integrated more easily into FQHCs that had other ongoing projects with similar requirements. These FQHCs were able to add requirements, such as reporting success rates and missed opportunities to clinicians, without the need to establish a new process. This limited the complexity of integrating new activities into existing processes. |
|
| ||
| Written protocols and processes | 3 | In addition to human capital, processes were also important to implementation. FQHCs that developed a written plan found this process to be helpful for ensuring step-by-step tasks were completed. Uniformity of procedures, such as when to follow up with patients who are due for vaccination were also useful, particularly for those who had multiple FQHCs in their FQHC system. These plans were typically written in advance of the program being implemented, but they were adaptable, and could be changed to meet shifting requirements. |
| Previsit planning | 3 | A key process change discussed in several FQHCs was the identification of patients eligible for HPV vaccination before appointments. This change was particularly helpful for FQHCs that did not already have similar programs in place. These FQHCs found the training in methods for identifying potential HPV vaccine candidates helpful for starting this new process of provider counseling. |
| FQHC visits | 2 | FQHC visits by ACS staff were important for “hold[ing] people accountable” to the objectives of the intervention. Additionally, the in-person interaction helped to solidify relationships between ACS representatives and clinic staff members. |
|
| ||
| Staff knowledge | 2 | Staff familiarity and comfort level with HPV vaccine were important facilitators. Staff knowledge of facts of HPV was important in building a general knowledge base for justifying the importance of the vaccine and the scheduled series. This knowledge also extended to building comfort in discussing the vaccine with patients through increased levels of confidence in staff members’ ability to answer patients’ questions. |
|
| ||
| Families and family buy-in | 2 | Addressing the wide variety of family needs across different patient populations was critical for meeting the goals of this project. For example, some patient populations had no firsthand knowledge of vaccine-preventable illnesses and so relied on their provider’s knowledge. Providers sometimes stated they had or they would give the vaccine to their own children. Other families had emigrated from locations where vaccine-preventable diseases were prevalent; these first- and second-generation immigrants were very amendable to preventive vaccines because of their recent history. |
|
| ||
|
| ||
| Incomplete program information from ACS | 3 | Three FQHCs reported receiving incomplete program information from ACS. Without a full understanding of what was required of them, the FQHCs ran into issues with running reports on short timelines and being unable to prepare their staff for what was required of them on the project. |
| Vaccine supply acquisition | 2 | Two FQHCs mentioned that they had issues ordering the vaccine and keeping the vaccine in stock. One FQHC recounted the process in which they transitioned from the Gardasil 4 vaccine to the Gardasil 9 vaccine (Gardasil 4 prevents 4 types of HPV and Gardasil 9 prevents 9 types of HPV). Another FQHC reported they had increased the number of HPV vaccinations in their FQHC to the extent that they ran out of the vaccine and had to rush to get more in stock. One director of quality and clinical practice manager recounted, “The financial piece of how we were acquiring vaccines created a little bit of difficulty because since we’re getting it through a 340B program which is a discounted price. And we weren’t dealing directly with the vendor. We weren’t able to initially move away from Gardasil 4 and get the Gardasil 9. So that was kind of a difficult transition since obviously we had to finish those doses of Gardasil 4.” |
|
| ||
| Patient reach | 3 | Another issue related to patients was reaching the appropriate patient population and difficulty with having children come to clinic for well-child appointments. At the time of the study, 3 appointments were required to vaccinate against HPV. FQHCs reported higher success rates with the first vaccination, because it aligned with other vaccines that are required for school attendance, but the second and third doses was a problem for this hard-to-reach age group. |
| Communication between providers and caregivers | 3 | The quality of communication among people both within the organization and with parents and patients has the potential to affect the implementation process. Three FQHCs had problems coordinating communication among a diverse group of clinician and nonclinicians with various schedules and responsibilities. Communication with parents and patients was also a challenge, particularly given the framing of HPV vaccine as a choice rather than a requirement. One director of quality and risk management stated, “You have to be careful how you present it to the parent as well. Since it’s not required most parents don’t want their child to have it.” |
| Insurance provider coverage issues | 3 | Three FQHCs described problems related to billing insurance companies for HPV vaccination. Even though the Centers for Disease Control and Prevention recommends vaccination starting at age 9, some insurance companies will not reimburse for children younger than 11. FQHCs reported that even if they are committed to this project and want to increase vaccine uptake, outside factors such as inconsistent insurance reimbursement hinder their progress. |
Abbreviations: ACS, American Cancer Society; FQHC, federally qualified health center; HPV, human papillomavirus.
The facilitators and barriers described in this table were noted by 2 or 3 FQHCs, whereas the facilitators and barriers described in the text were noted by at least 4 FQHCs.
FigureMajor themes of barriers and facilitators to implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program across domains of the Consolidated Framework for Implementation Research (CFIR), May–August 2016. This figure does not show all possible constructs, because the federally qualified health centers participating in the study did not report barriers or facilitators for every construct.
Magnitudea of Facilitators by Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program, May–August 2016
| Facilitator | Received $90,000 | Received $10,000 | Received Technical Assistance Only | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5 | 6 | 7 | 8 | 9 | 3 | 4 | 2 | 1 | |
|
| |||||||||
| Compatibility with other similar projects |
|
| |||||||
|
| |||||||||
| Staff knowledge |
|
| |||||||
|
| |||||||||
| Trainings and education |
|
|
|
|
| ||||
| Tools and resources |
|
|
|
|
| ||||
| Written protocols and processes |
|
|
| ||||||
| ACS staff support |
|
|
|
|
|
|
| ||
| EHR system |
|
|
|
|
|
|
| ||
| Quality improvement team |
| ||||||||
| Previsit planning |
|
|
| ||||||
| Site visits |
|
| |||||||
| Provider champions |
|
|
|
|
| ||||
|
| |||||||||
| Leadership support |
|
|
|
| |||||
| Clinic staff support |
|
|
|
|
| ||||
| Communication |
|
|
|
| |||||
| Teamwork |
|
|
| ||||||
|
| |||||||||
| Patient needs: families/family buy-in |
|
| |||||||
| Cosmopolitanism: other partnerships (pharmaceutical companies/schools) |
|
| |||||||
Abbreviations: ●, 1 Participant noted facilitator; ■, ≥2 Participants noted facilitator; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
“Magnitude” refers to the extent to which the constructs were discussed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC systems implemented the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a $90,000 2-year grant, another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine FQHCs were selected to participate in qualitative interviews.
Magnitudea of Barriers by Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program, May–August 2016
| Barrier | Received $90,000 | Received $10,000 | Received Technical Assistance Only | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5 | 6 | 7 | 8 | 9 | 3 | 4 | 2 | 1 | |
|
| |||||||||
| Incomplete program info from ACS | ● | ■ | ● | ||||||
|
| |||||||||
| Inconsistent implementation between providers | ● | ● | |||||||
|
| |||||||||
| Vaccine acquisition | ● | ● | |||||||
| EHR issues | ● | ● | ■ | ● | ■ | ● | ● | ■ | |
| Staff resources and time | ■ | ■ | ■ | ● | ■ | ■ | ■ | ■ | |
| Patient reach | ● | ● | ● | ||||||
|
| |||||||||
| Program incompatibility | ● | ● | ● | ● | |||||
| Communication | ● | ● | ■ | ||||||
| Staff buy-in | ● | ● | ● | ● | ■ | ||||
| Competing priorities | ● | ● | ● | ● | ● | ● | ■ | ||
| Training needs | ● | ● | ■ | ● | ■ | ||||
| Level of ACS funding/cost of program | ■ | ● | ● | ● | ● | ||||
|
| |||||||||
| Low health literacy | ● | ● | ● | ● | |||||
| Immigrant population | ● | ● | |||||||
| Cultural barriers/language barriers | ■ | ● | ● | ● | ● | ||||
| Time restrictions for patients | ■ | ||||||||
| Patient misinformation/ vaccine stigma | ■ | ● | ■ | ● | ● | ■ | ● | ● | |
| Insurance provider coverage issues | ● | ■ | ● | ||||||
| State registry issues | ■ | ■ | ● | ● | ● | ■ | |||
Abbreviations: ●, 1 FQHC noted barrier; ■, ≥2 FQHCs noted barrier; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
“Magnitude” refers to the extent to which the constructs were discussed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC systems implemented the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a $90,000 2-year grant, another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine FQHCs were selected to participate in qualitative interviews.
Valencea of Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program, May–August 2016
| Construct | Received $90,000 | Received $10,000 | Received Technical Assistance Only | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5 | 6 | 7 | 8 | 9 | 3 | 4 | 2 | 1 | |
|
| |||||||||
| Evidence of strength | 0 | 0 | 0 | − | 0 | − | 0 | 0 | − |
|
| |||||||||
| Knowledge | − | 0 | 0 | 0 | 0 | + | 0 | + | − |
|
| |||||||||
| Planning: vaccine acquisition and previsit planning | 0 | 0 | + | 0 | 0 | + | 0 | 0 | + |
| Executing | +/− | +/− | +/− | +/− | +/− | − | +/− | +/− | +/− |
| Champions (providers) | + | 0 | + | 0 | 0 | 0 | + | + | + |
| External change agents (ACS staff) | + | + | + | 0 | + | 0 | + | + | + |
|
| |||||||||
| Compatibility | +/− | 0 | − | + | 0 | − | 0 | 0 | − |
| Network and communication | − | 0 | +/− | + | + | − | + | + | + |
| Implementation climate: staff buy-in | − | 0 | +/− | + | − | 0 | +/− | + | +/− |
| Relative priority: competing priorities | − | − | − | − | 0 | 0 | − | − | − |
| Leadership engagement | 0 | 0 | 0 | 0 | + | + | + | + | 0 |
| Access to knowledge: training needs | − | − | 0 | − | 0 | − | − | 0 | 0 |
| Available resources: level of ACS funding/cost of program | − | 0 | 0 | 0 | 0 | − | − | − | − |
|
| |||||||||
| Patient needs | − | − | +/− | − | 0 | 0 | + | − | 0 |
| Policies and mandates: insurance provider coverage issues | − | 0 | − | 0 | 0 | 0 | 0 | − | 0 |
| Cosmopolitanism | +/− | 0 | − | 0 | +/− | 0 | − | − | − |
Abbreviations: +, positive effect on implementation; −, negative effect on implementation. +/−, mixed effect on implementation, “0”=theme not mentioned in the interview; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
“Valence” refers to the construct’s influence on implementation of the program. We considered valence to be positive (facilitated implementation of the intervention), negative (hindered the implementation), or mixed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC systems implemented the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a $90,000 2-year grant, another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine FQHCs were selected to participate in qualitative interviews.
| CFIR Constructs | Barrier | Facilitator |
|---|---|---|
|
| ||
| Design quality | 3 | 0 |
| Cost | 5 | 0 |
|
| ||
| Patient needs and resources: family buy-in | 0 | 2 |
| Patient needs and resources: patient misinformation/vaccine stigma | 8 | 0 |
| Patient needs and resources: cultural/language barriers | 5 | 0 |
| Patient needs and resources: low health literacy | 4 | 0 |
| External policies and incentives | 9 | 0 |
| Cosmopolitanism and peer pressure | 0 | 2 |
|
| ||
| Networks and communications | 3 | 6 |
| Implementation climate: compatibility | 0 | 3 |
| Implementation climate: relative priority | 7 | 0 |
| Readiness for implementation: leadership engagement | 0 | 4 |
| Readiness for implementation: available resources | 9 | 5 |
|
| ||
| Planning | 3 | 6 |
| Engaging | 5 | 5 |
| Champions/opinion leaders | 0 | 5 |
| External change agents | 0 | 2 |
| Executing | 8 | 7 |
| Reflecting and evaluating | 0 | 3 |
|
| ||
| Knowledge and beliefs about the intervention | 0 | 2 |